Company intelligence / Profile preview
ImmunoGen
Waltham, Massachusetts, United Statesdrugtargetreview.com ↗
- Ownership
- Public · IMGN
- Employees
- ~75
- Development stage
- Commercial
01
Overview
ImmunoGen developed ELAHERE (mirvetuximab soravtansine-gynx), a first-in-class ADC approved for platinum-resistant ovarian cancer (PROC), showing meaningful survival benefit. The company was acquired by AbbVie in a $10.1 billion deal announced in November 2023[4].
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
26 assets25 more assets in the full pipeline.
Request access →03
Partnerships
04
Financials
- Market cap
- $8.7B
- Total revenue
- $113.4M
- Enterprise value
- $8.2B
Beyond the preview
Go deeper on ImmunoGen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImmunoGen.